渴络欣胶囊联合西药治疗糖尿病肾病的系统评价与Meta分析
该系统评价与Meta分析纳入20项RCT共1500例糖尿病肾病患者,评估渴络欣胶囊联合西药对比单用西药的疗效与安全性。结果显示联合治疗在改善eGFR、降低mALB、UAER、24hUpro、Scr、BUN、FBG、TC、TG、LDL方面优于单用西药,HbA1c与不良事件无显著差异。结论认为联合治疗有积极效果,但受异质性和研究质量限制,仍需大样本严格设计的RCT验证。
要点
- 渴络欣胶囊联合西药可改善DKD患者eGFR及多项蛋白尿指标。
- 联合治疗对FBG、TC、TG、LDL有改善,但HbA1c无显著差异。
- 不良事件无显著差异,但纳入研究异质性高、质量偏低。
核心结论
- 渴络欣胶囊联合西药对糖尿病肾病具有积极疗效,但受临床异质性高和纳入研究质量低限制,仍需标准化大样本严格设计的RCT验证。
研究设计与样本
- 系统评价与Meta分析,检索7个中英文数据库至2022年6月3日,纳入20项RCT共1500例糖尿病肾病患者。
- 采用Cochrane RoB 2工具评估方法学质量与偏倚风险,使用RevMan 5.4和Stata 17.0进行分析。
主要发现
- 联合治疗改善eGFR [MD=3.04, 95%CI(0.30,5.78), p=0.03]。
- 联合治疗降低mALB [MD=-25.83, 95%CI(-41.20,-10.47), p=0.001]和UAER [SMD=-0.97, 95%CI(-1.50,-0.44), p=0.0003]。
- 联合治疗降低24hUpro [SMD=-1.31, 95%CI(-1.82,-0.80), p<0.00001]和Scr [MD=-11.39, 95%CI(-18.76,-4.02), p=0.002]。
- 联合治疗降低BUN [MD=-1.28, 95%CI(-1.67,-0.88), p<0.00001]和FBG [MD=-0.51, 95%CI(-0.90,-0.11), p=0.01]。
- 联合治疗降低TC [MD=-1.04, 95%CI(-1.40,-0.68), p<0.00001]、TG [MD=-0.36, 95%CI(-0.50,-0.23), p<0.00001]和LDL [MD=-0.39, 95%CI(-0.71,-0.07), p=0.02]。
关键数值与推荐
- HbA1c组间差异无统计学意义(p=0.14)。
- 不良事件组间差异无统计学意义(p=0.81)。
临床怎么用
- 在糖尿病肾病患者中,可考虑渴络欣胶囊联合西药以改善肾功能、蛋白尿及血脂指标。
- 联合治疗对血糖的改善需结合HbA1c无显著差异综合判断,不应仅依据FBG变化调整降糖方案。
- 应用时需关注研究异质性与低质量证据,疗效结论需结合患者个体情况谨慎解读。
局限性
- 纳入研究临床异质性高且质量偏低,可能影响结果可靠性。
- 仍需标准化、大规模、严格设计的RCT在DKD definitive阶段进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: Keluoxin capsule (KLXC) has been widely used in diabetic kidney disease (DKD), but its efficacy and safety have not yet been clarified. A systematic review and meta-analysis were performed to assess the efficacy and safety of KLXC for DKD. Methods: The randomized control trials (RCTs) included KLXC searched from seven major English and Chinese databases up until 3 June 2022. The methodological quality and risk of bias were assessed by version 2 of the Cochrane risk-of-bias tool (RoB 2) for the RCTs from the Cochrane Handbook. The analyses were conducted by RevMan 5.4 and Stata 17.0. Results: A total of 20 trials with 1,500 participants were identified. The meta-analysis showed that KLXC combined with Western medicine was superior to the use of Western medicine alone for DKD which included improvements in the estimated glomerular filtration rate (eGFR) [MD = 3.04, 95% CI (0.30, 5.78), p = 0.03], reduction in microalbuminuria (mALB) [MD = -25.83, 95% CI (-41.20, -10.47), p = 0.001], urinary albumin excretion rate (UAER) [SMD = -0.97, 95% CI (-1.50, -0.44), p = 0.0003], 24-h urine protein (24hUpro) [SMD = -1.31, 95% CI (-1.82, -0.80), p < 0.00001], serum creatinine (Scr) [MD = -11.39, 95% CI (-18.76, -4.02), p = 0.002], blood urea nitrogen (BUN) [MD = -1.28, 95% CI (-1.67, -0.88), p < 0.00001], fasting blood glucose (FBG) [MD = -0.51, 95% CI (-0.90, -0.11), p = 0.01], total cholesterol (TC) [MD = -1.04, 95% CI (-1.40, -0.68), p < 0.00001], triglycerides (TG) [MD = -0.36, 95% CI (-0.50, -0.23), p < 0.00001], and low-density lipoprotein cholesterol (LDL) [MD = -0.39, 95% CI (-0.71, -0.07), p = 0.02]. Results showed no statistically significant difference in glycated hemoglobin (HbA1c) (p = 0.14) or adverse events (p = 0.81) between the two groups. Conclusion: The combination of KLXC and Western medicine had a positive effect on DKD. However, due to the high clinical heterogeneity and low quality of included studies, further standardized, large-scale, rigorously designed RCTs for DKD in the definitive stage are still necessary to achieve more accurate results. Systematic Review Registration: https://inplasy.com/inplasy-2021-11-0067/, identifier INPLASY 2021110067.
引用
- Zhang W, Zhou J, Wang C, et al. Efficacy and safety of Keluoxin capsule in combination with Western medicine for diabetic kidney disease: A systematic review and meta-analysis. Front Pharmacol. 2023. PMID: 36686708. doi:10.3389/fphar.2022.1052852
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。